Evaluating Multiple Drug Regimens and Treatment Durations for Pulmonary Tuberculosis in a Global Phase 2BC Platform Trial
Led by University College, London · Updated on 2026-10-15
2500
Participants Needed
11
Research Sites
24 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating new treatment regimens for pulmonary tuberculosis TB that aim to be faster while maintaining safety and effectiveness. This trial is conducted by the UNITE4TB consortium, a collaboration of universities and pharmaceutical companies, funded by the European Union. The study focuses on adults with newly diagnosed rifampicin-susceptible pulmonary TB and includes both drug-susceptible and potentially drug-resistant cases to find improved therapies.
The trial has two main parts. In Phase 2B, up to 700 participants will be randomly assigned to one of several treatment groups, including a standard 24-week regimen and up to 16-week novel regimens combining new drugs like BTZ-043 and GSK3036656 with existing TB medications. Phase 2C will involve up to 1800 participants receiving selected regimens from Phase 2B for varying durations between 8 and 16 weeks. The study drugs are given orally with specific doses, and treatment combinations may change during the trial.
Participants will be followed for a total of 72 weeks to monitor treatment response and safety. Assessments include measuring the time to positivity of sputum cultures, adverse events, and treatment outcomes such as relapse or failure. Safety monitoring covers serious and special interest adverse events. The trial includes regular visits and laboratory tests to evaluate the effectiveness and tolerability of the treatments over the duration of the study.
CONDITIONS
Brief Title
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Research Team
S
Susie Slater
K
Karen Sanders
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Current alcohol or drug use compromising safety or adherence
Use of amphetamines or methamphetamines
Other significant medical or social conditions affecting safety or compliance
Pregnant or breastfeeding women
Women of childbearing potential not using effective contraception during and 14 days after treatment
Men unwilling to use condoms during and 90 days after treatment
Known allergy to study drugs
Use of medications interacting with study drugs unless stopped safely
Use of medications prolonging QTc interval unless resolved before dosing
Immunosuppressive drugs within 2 weeks before screening (with exceptions)
Participation in another investigational trial within 8 weeks
ECG abnormalities including QTcF >450ms (men) or >460ms (women)
Laboratory abnormalities including low hemoglobin, platelet, or neutrophil counts, reduced kidney function, high liver enzymes, abnormal electrolytes
Positive hepatitis B surface antigen
Positive HIV antibody test
Known hepatitis C infection without negative PCR test
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial screening visit including medical evaluation and tests
Phase 2B Treatment
Duration - 16 weeks
Participants are randomly assigned to receive either the standard 24-week TB treatment or one of several new drug combinations for 16 weeks to evaluate safety and effectiveness.
Regular visits during treatment for monitoring and assessments
Phase 2C Treatment
Duration - 8 to 24 weeks depending on assigned group
Participants receive selected treatment regimens for varied durations between 8 and 16 weeks, or continue the standard 24-week treatment, to determine optimal treatment length.
Scheduled visits throughout treatment for monitoring and safety checks
Follow-up
Duration - Up to 72 weeks
Participants are monitored for treatment outcomes and safety for a total of 72 weeks from randomization.
Periodic follow-up visits including sputum tests and safety assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
17
Similar Trials
Multi-Center Study of a Shortened Treatment Regimen Using Bedaquiline, Linezolid, Sitafloxacin, and Pyrazinamide for Drug-Sensitive and Drug-Resistant Pulmonary Tuberculosis
Study of Atorvastatin Doses Added to Standard Treatment for Pulmonary Tuberculosis in Patients Aged 12 to 65
Evaluating Combined Channa Striata and Curcuma Domestica Supplementation to Improve Nutrition, Inflammation, and Quality of Life in Adults with Active Pulmonary Tuberculosis
Study of Breath Biomarkers to Identify and Diagnose Various Lung Diseases Using Advanced AI Technology
Testing a High-Dose Triple-Drug Regimen for Treating Recurrent Tuberculosis
Comparing Safety and Effectiveness to Standard Treatment in Patients with Rifampicin-Susceptible TB
Phase 2BC Study Comparing New and Standard Drug Treatments for Adults With Newly Diagnosed Drug-Sensitive Pulmonary Tuberculosis
Evaluating Multiple Drug Regimens and Treatment Durations for Pulmonary Tuberculosis in a Global Phase 2BC Platform Trial
Study on Pulmonary Rehabilitation to Improve Function and Quality of Life in Adults with Post-Tuberculosis Lung Disease
Evaluating a 4-Month Short Treatment for Low Risk Active Pulmonary Tuberculosis Compared to the Standard 6-Month Regimen
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).
Xianfeng Li, Vincent Hernandez, Fernando L Rock...
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.